Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD (NCT07309471) | Clinical Trial Compass
RecruitingNot Applicable
Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD
Switzerland24 participantsStarted 2026-03-06
Plain-language summary
This study investigates DDH-LSD, a novel LSD-like compound expected to have a shorter duration of action than LSD. In healthy volunteers, pharmacokinetics, safety, and subjective effects, will be assessed and compare with LSD in a controlled cross-over study.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 25 and 65 years old
✓. Sufficient understanding of the German language
✓. Understanding of procedures and risks associated with the study
✓. Willing to adhere to the protocol and signing of the consent form
✓. Willing to refrain from the consumption of illicit psychoactive substances during the study
✓. Abstaining from xanthine-based liquids from the evenings prior to the study sessions and during the sessions
✓. Willing not to operate heavy machinery within 48 h of substance administration
✓. Willing to use effective contraceptive measures throughout study participation
Exclusion criteria
✕. Chronic or acute medical condition
✕. Current or previous major psychiatric disorder
✕. Psychotic disorder or bipolar disorder in first-degree relatives
✕. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg)
✕. Use of hallucinogenic substances (not including cannabis) more than 20 times or any time within the previous two months
What they're measuring
1
Determine effective DDH-LSD dose
Timeframe: During each 13-hour study session.
2
Compare duration of action and elimination half-life